Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00869011

Enrollment

Registered

2009-03-25

Start date

2009-12-31

Completion date

Unknown

Last updated

2009-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Keywords

Cancer, renal cell carcinoma, fatigue, exercise

Brief summary

In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with Sunitinib.

Interventions

OTHEREndurance exercise

Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* 18 to 75 years * Understanding of written German * Treatment with Sunitinib * Ability to walk

Exclusion criteria

* Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise * BMI \< 18 or \> 30

Design outcomes

Primary

Measure	Time frame
Fatigue	12 weeks

Secondary

Measure	Time frame
VO2max	12 weeks
Systolic and diastolic blood pressure (24 h)	12 weeks
Depression score	12 weeks

Countries

Germany

Contacts

Primary ContactFernando C. Dimeo, MD

fernando.dimeo@charite.de+493084452098

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026